眼科医疗概念股盘中拉升，莎普爱思午后涨停，兴齐眼药涨超10%，立方制药此前涨停，百诚医药、爱 博医疗、光正眼科、何氏眼科等跟涨。 ...

Market Overview - The medical services sector rose by 3.64% on August 29, with the leading stock being Puris [1] - The Shanghai Composite Index closed at 3857.93, up 0.37%, while the Shenzhen Component Index closed at 12696.15, up 0.99% [1] Top Gainers in Medical Services - Zenggansi (301257) closed at 43.54, up 20.01% with a trading volume of 64,900 shares and a turnover of 278 million [1] - Haoyuan Pharmaceutical (688131) closed at 68.48, up 13.70% with a trading volume of 189,200 shares and a turnover of 1.256 billion [1] - Bidai Pharmaceutical (688073) closed at 67.11, up 10.43% with a trading volume of 28,300 shares and a turnover of 182 million [1] - Meidi Xi (688202) closed at 64.21, up 8.96% with a trading volume of 124,400 shares and a turnover of 784 million [1] - WuXi AppTec (603259) closed at 103.30, up 7.95% with a trading volume of 1,016,600 shares and a turnover of 10.18 billion [1] Top Losers in Medical Services - Digital Human (835670) closed at 17.54, down 6.20% with a trading volume of 127,200 shares and a turnover of 227 million [2] - Puri Eye Hospital (301239) closed at 40.78, down 4.63% with a trading volume of 49,600 shares and a turnover of 203 million [2] - Yingkang Life (300143) closed at 10.64, down 3.45% with a trading volume of 230,300 shares and a turnover of 250 million [2] Capital Flow in Medical Services - The medical services sector saw a net inflow of 1.259 billion from institutional investors, while retail investors experienced a net outflow of 446 million [2][3] - Major stocks like WuXi AppTec had a net inflow of 1.269 billion from institutional investors, while it faced a net outflow of 741 million from retail investors [3]

Group 1 - The A-share market saw a significant rise in CRO concept stocks, with notable increases in share prices for several companies [1] - Haoyuan Pharmaceutical experienced a rise of over 15%, while Chengdu XianDao and MeidiXi saw increases of over 11% and 10% respectively [1] - Other companies such as Bid Pharma, Boteng Co., and WuXi AppTec also reported gains exceeding 7% [1] Group 2 - The following table summarizes the performance of key CRO stocks, including their percentage increase, total market capitalization, and year-to-date performance [2] - Haoyuan Pharmaceutical: +15.19%, Market Cap: 14.7 billion, YTD: +95.07% - Chengdu XianDao: +11.02%, Market Cap: 10.7 billion, YTD: +116.70% - MeidiXi: +10.54%, Market Cap: 8.75 billion, YTD: +115.91% - Bid Pharma: +8.39%, Market Cap: 5.99 billion, YTD: +36.61% - Boteng Co.: +7.51%, Market Cap: 13.6 billion, YTD: +58.02% - WuXi AppTec: +7.43%, Market Cap: 303.4 billion, YTD: +90.82% - Sunshine Nuohe: +6.32%, Market Cap: 8.46 billion, YTD: +100.86% - Baicheng Pharmaceutical: +4.97%, Market Cap: 6.29 billion, YTD: +51.90% - Kailai Ying: +4.49%, Market Cap: 39 billion, YTD: +43.98% - NuoSiGe: +4.35%, Market Cap: 5.19 billion, YTD: +7.82% [2]

Group 1 - The core viewpoint of the news is that Baicheng Pharmaceutical (301096.SZ) reported its semi-annual results for 2025, revealing significant institutional investor activity and changes in shareholding [1] - As of August 27, 2025, a total of 10 institutional investors disclosed holdings in Baicheng Pharmaceutical A-shares, with a combined holding of 14.74 million shares, accounting for 13.50% of the total share capital [1] - The top ten institutional investors include various management partnerships and funds, with their combined holding percentage decreasing by 1.07 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, one fund, Rongtong Health Industry Flexible Allocation Mixed A/B, reported a slight decrease in holdings compared to the previous quarter [2] - Two new public funds were disclosed during this period, namely Caitong Technology Innovation Mixed A and Caitong Fusheng Mixed Initiation (LOF) A [2] - Two public funds, including Everbright Baodexin Credit Enhancement Bond Class A and Everbright Baodexin Anqi Bond Class A, were not disclosed in this period compared to the previous quarter [2]

（文章来源：证券日报） 证券日报网讯百诚医药8月28日在互动平台回答投资者提问时表示，2025年上半年，根据公司业务发展 规划和行业发展情况，公司调整和优化了人员结构，持续推进资源配置优化、费用管控等降本增效举 措，争取努力提升公司经营效益。围绕中长期布局规划，公司始终保持着在人才、技术战略方面保持较 高水平的研发投入。 ...

（文章来源：证券日报） 证券日报网讯百诚医药8月28日在互动平台回答投资者提问时表示，销售费用较低主要系公司所从事的 业务为研发驱动型，主要业务来自于市场口碑与客户的介绍。未来公司将不断拓展合作渠道，动态调整 营销策略，寻求国内外新的业务合作机会，优化经营管理，努力推动公司稳定经营、健康发展。 ...

证券日报网讯百诚医药8月28日在互动平台回答投资者提问时表示，稳心颗粒（无蔗糖）为公司研发持 有的首个获批"澳门监制"同名同方药，对标产品为步长药业的稳心颗粒。上市后的营收表现请关注公司 的定期报告。公司未来会结合自身的实际情况以及业务进展，制定其他创新药的上市策略。 （文章来源：证券日报） ...

Core Viewpoint - 百诚医药's stock experienced a decline of 2.27% on August 27, with a trading volume of 208 million yuan, indicating a challenging market environment for the company [1] Financing Summary - On August 27, 百诚医药 had a financing buy-in amount of 22.37 million yuan and a financing repayment of 18.86 million yuan, resulting in a net financing buy of 3.51 million yuan [1] - As of August 27, the total financing and securities lending balance for 百诚医药 was 197 million yuan, with the financing balance at 196 million yuan, accounting for 3.28% of the circulating market value, which is above the 60th percentile over the past year [1] - The company had no shares repaid in securities lending on August 27, with 100 shares sold, amounting to 5,480 yuan at the closing price, and a securities lending balance of 42,200 yuan, exceeding the 70th percentile over the past year [1] Financial Performance Summary - As of June 30, 百诚医药 had 11,900 shareholders, a decrease of 26.69% from the previous period, while the average circulating shares per person increased by 62.65% to 6,976 shares [2] - For the first half of 2025, 百诚医药 reported a revenue of 332 million yuan, a year-on-year decrease of 36.70%, and a net profit attributable to shareholders of 3.10 million yuan, down 97.69% year-on-year [2] - Since its A-share listing, 百诚医药 has distributed a total of 184 million yuan in dividends, with 119 million yuan distributed over the past three years [2] Shareholding Summary - As of June 30, 2025, the eighth largest circulating shareholder of 百诚医药 was融通健康产业灵活配置混合A/B, holding 1.20 million shares, a decrease of 100,000 shares from the previous period [2] - 光大保德信信用添益债券 A类 exited the list of the top ten circulating shareholders [2]

据证券之星公开数据整理，近期百诚医药（301096）发布2025年中报。截至本报告期末，公司营业总收 入3.32亿元，同比下降36.7%，归母净利润309.82万元，同比下降97.69%。按单季度数据看，第二季度 营业总收入2.04亿元，同比下降34.18%，第二季度归母净利润2929.58万元，同比下降65.29%。本报告 期百诚医药三费占比上升明显，财务费用、销售费用和管理费用总和占总营收同比增幅达58.28%。 本次财报公布的各项数据指标表现不尽如人意。其中，毛利率50.73%，同比减26.21%，净利率0.93%， 同比减96.35%，销售费用、管理费用、财务费用总计6722.32万元，三费占营收比20.23%，同比增 58.28%，每股净资产23.64元，同比减8.04%，每股经营性现金流-1.05元，同比减20.24%，每股收益0.03 元，同比减97.58% 分析师工具显示：证券研究员普遍预期2025年业绩在1785.0万元，每股收益均值在0.16元。 | 项目 | 2024年中报 | 2025年中报 | 同比增幅 | | --- | --- | --- | --- | | 营业总收入(元) | ...

百诚医药(301096.SZ)发布2025年半年度报告，该公司营业收入为3.32亿元，同比减少36.70%。归属于上 市公司股东的净利润为309.82万元，同比减少97.69%。归属于上市公司股东的扣除非经常性损益的净亏 损为1173.01万元。基本每股收益为0.03元。 ...